CANCER:

Lung Adenocarcinoma

Related cancers:

‹

Non Small Cell Lung Cancer (2230)

Lung Non-Small Cell Squamous Cancer (76)

Lung Non-Squamous Non-Small Cell Cancer (76)

Non Small Cell Lung Cancer (2230)

Lung Non-Small Cell Squamous Cancer (76)

Lung Non-Squamous Non-Small Cell Cancer (76)

›

ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	alectinib Sensitive: C4 – Case Studies Dovepress - 1 day	alectinib Sensitive: C4 – Case Studies Dovepress - 1 day
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	anlotinib Resistant: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week	anlotinib Resistant: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	pembrolizumab + anlotinib Sensitive: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week	pembrolizumab + anlotinib Sensitive: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week
HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	ado-trastuzumab emtansine + mobocertinib Resistant: D – Preclinical Cancer Res - 1 week	ado-trastuzumab emtansine + mobocertinib Resistant: D – Preclinical Cancer Res - 1 week
HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20 YVMA insertion HER-2 exon 20 YVMA insertion	Lung Adenocarcinoma LUAD	mobocertinib Resistant: D – Preclinical Cancer Res - 1 week	mobocertinib Resistant: D – Preclinical Cancer Res - 1 week
HER-2 exon 20G776>VC insertion HER-2 exon 20G776>VC insertion	Lung Adenocarcinoma LUAD	HER-2 exon 20G776>VC insertion HER-2 exon 20G776>VC insertion	Lung Adenocarcinoma LUAD	mobocertinib Sensitive: D – Preclinical Cancer Res - 1 week	mobocertinib Sensitive: D – Preclinical Cancer Res - 1 week
EGFR C797S EGFR C797S	Lung Adenocarcinoma LUAD	EGFR C797S EGFR C797S	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials Cancer Med - 2 weeks	brigatinib Sensitive: C3 – Early Trials Cancer Med - 2 weeks
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials Cancer Med - 2 weeks	brigatinib Sensitive: C3 – Early Trials Cancer Med - 2 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	brigatinib Sensitive: C3 – Early Trials Cancer Med - 2 weeks	brigatinib Sensitive: C3 – Early Trials Cancer Med - 2 weeks
DVL2 rs2074216G>A DVL2 rs2074216G>A	Lung Adenocarcinoma LUAD	DVL2 rs2074216G>A DVL2 rs2074216G>A	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 3 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 3 weeks
ARF1 rs11541557G>T ARF1 rs11541557G>T	Lung Adenocarcinoma LUAD	ARF1 rs11541557G>T ARF1 rs11541557G>T	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 3 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 3 weeks
UHRF1 rs2261988C>A UHRF1 rs2261988C>A	Lung Adenocarcinoma LUAD	UHRF1 rs2261988C>A UHRF1 rs2261988C>A	Lung Adenocarcinoma LUAD	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 3 weeks	EGFR inhibitor Resistant: C3 – Early Trials Dovepress - 3 weeks
GHR-ALK fusion GHR-ALK fusion	Lung Adenocarcinoma LUAD	GHR-ALK fusion GHR-ALK fusion	Lung Adenocarcinoma LUAD	crizotinib Resistant: C4 – Case Studies J Int Med Res - 3 weeks	crizotinib Resistant: C4 – Case Studies J Int Med Res - 3 weeks
SLC8A1-ALK fusion SLC8A1-ALK fusion	Lung Adenocarcinoma LUAD	SLC8A1-ALK fusion SLC8A1-ALK fusion	Lung Adenocarcinoma LUAD	crizotinib Resistant: C4 – Case Studies Dovepress - 3 weeks	crizotinib Resistant: C4 – Case Studies Dovepress - 3 weeks
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	alectinib + brigatinib Resistant: C4 – Case Studies Medicine (Baltimore) - 3 weeks	alectinib + brigatinib Resistant: C4 – Case Studies Medicine (Baltimore) - 3 weeks
EGFR L747P EGFR L747P	Lung Adenocarcinoma LUAD	EGFR L747P EGFR L747P	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks	afatinib Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks
EGFR T790M + EGFR S768I + EGFR L858R EGFR T790M + EGFR S768I + EGFR L858R	Lung Adenocarcinoma LUAD	EGFR T790M + EGFR S768I + EGFR L858R EGFR T790M + EGFR S768I + EGFR L858R	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials Thorac Cancer - 4 weeks	afatinib Resistant: C3 – Early Trials Thorac Cancer - 4 weeks
EGFR T790M + EGFR L833V +EGFR H835L EGFR T790M + EGFR L833V +EGFR H835L	Lung Adenocarcinoma LUAD	EGFR T790M + EGFR L833V +EGFR H835L EGFR T790M + EGFR L833V +EGFR H835L	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials Thorac Cancer - 4 weeks	afatinib Resistant: C3 – Early Trials Thorac Cancer - 4 weeks
EGFR L833V + EGFR H835L EGFR L833V + EGFR H835L	Lung Adenocarcinoma LUAD	EGFR L833V + EGFR H835L EGFR L833V + EGFR H835L	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks	afatinib Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks
EGFR A767_V769dup EGFR A767_V769dup	Lung Adenocarcinoma LUAD	EGFR A767_V769dup EGFR A767_V769dup	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks	afatinib Sensitive: C3 – Early Trials Thorac Cancer - 4 weeks
SDC4-ROS1 fusion + ROS1-GK fusion SDC4-ROS1 fusion + ROS1-GK fusion	Lung Adenocarcinoma LUAD	SDC4-ROS1 fusion + ROS1-GK fusion SDC4-ROS1 fusion + ROS1-GK fusion	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies Pulm Med - 4 weeks	crizotinib Sensitive: C4 – Case Studies Pulm Med - 4 weeks
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval	nintedanib Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	PD-L1 underexpression PD-L1 underexpression	Lung Adenocarcinoma LUAD	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	DP Sensitive: A2 - Guideline	DP Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	GC Sensitive: A2 - Guideline	GC Sensitive: A2 - Guideline
No biomarker No biomarker	Lung Adenocarcinoma LUAD	No biomarker No biomarker	Lung Adenocarcinoma LUAD	cisplatin + pemetrexed Sensitive: A2 - Guideline	cisplatin + pemetrexed Sensitive: A2 - Guideline
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	erlotinib Sensitive: B - Late Trials	erlotinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	erlotinib Resistant: B - Late Trials	erlotinib Resistant: B - Late Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	gefitinib Sensitive: B - Late Trials	gefitinib Sensitive: B - Late Trials
HER-2 exon 20 insertion + TMB-L + PD-L1 negative HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma LUAD	HER-2 exon 20 insertion + TMB-L + PD-L1 negative HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma LUAD	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C1 - Off-label	bevacizumab + erlotinib Sensitive: C1 - Off-label
PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	PD-L1 expression PD-L1 expression	Lung Adenocarcinoma LUAD	atezolizumab Sensitive: C1 - Off-label	atezolizumab Sensitive: C1 - Off-label
MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	MET exon 14 mutation MET exon 14 mutation	Lung Adenocarcinoma LUAD	tepotinib Sensitive: C1 - Off-label	tepotinib Sensitive: C1 - Off-label
EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion EGFR exon 19 deletion	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label	osimertinib Resistant: C1 - Off-label
BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	trametinib + dabrafenib Sensitive: C1 - Off-label	trametinib + dabrafenib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Lung Adenocarcinoma LUAD	ATM mutation ATM mutation	Lung Adenocarcinoma LUAD	olaparib Sensitive: C1 - Off-label	olaparib Sensitive: C1 - Off-label
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	osimertinib Resistant: C1 - Off-label	osimertinib Resistant: C1 - Off-label
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C1 - Off-label	osimertinib Sensitive: C1 - Off-label
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C1 - Off-label	erlotinib Sensitive: C1 - Off-label
RET fusion RET fusion	Lung Adenocarcinoma LUAD	RET fusion RET fusion	Lung Adenocarcinoma LUAD	pralsetinib Sensitive: C1 - Off-label	pralsetinib Sensitive: C1 - Off-label
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	lorlatinib Sensitive: C1 - Off-label	lorlatinib Sensitive: C1 - Off-label
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab Sensitive: C2 – Inclusion Criteria	bevacizumab Sensitive: C2 – Inclusion Criteria
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	trametinib Sensitive: C2 – Inclusion Criteria	trametinib Sensitive: C2 – Inclusion Criteria
EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C2 – Inclusion Criteria	erlotinib Sensitive: C2 – Inclusion Criteria
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C2 – Inclusion Criteria	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	EGFR L858R EGFR L858R	Lung Adenocarcinoma LUAD	bevacizumab + erlotinib Sensitive: C3 – Early Trials	bevacizumab + erlotinib Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	cetuximab + afatinib Sensitive: C3 – Early Trials	cetuximab + afatinib Sensitive: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR exon 19 deletion + PD-L1 overexpression EGFR exon 19 deletion + PD-L1 overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	bevacizumab + afatinib Sensitive: C3 – Early Trials	bevacizumab + afatinib Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR-RAD51 fusion EGFR-RAD51 fusion	Lung Adenocarcinoma LUAD	EGFR-RAD51 fusion EGFR-RAD51 fusion	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Lung Adenocarcinoma LUAD	EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	ALK rearrangement ALK rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	EGFR mutation EGFR mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	bevacizumab + osimertinib Resistant: C3 – Early Trials	bevacizumab + osimertinib Resistant: C3 – Early Trials
EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	EGFR L861Q EGFR L861Q	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	trastuzumab + pertuzumab Sensitive: C3 – Early Trials	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	EGFR G719X EGFR G719X	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
SNX20 overexpression + PD-L1 overexpression SNX20 overexpression + PD-L1 overexpression	Lung Adenocarcinoma LUAD	SNX20 overexpression + PD-L1 overexpression SNX20 overexpression + PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Lung Adenocarcinoma LUAD	TP53 mutation TP53 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Adenocarcinoma LUAD	EGFR mutation + KRAS mutation EGFR mutation + KRAS mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	PIK3CA mutation + PTEN deletion PIK3CA mutation + PTEN deletion	Lung Adenocarcinoma LUAD	osimertinib Sensitive: C3 – Early Trials	osimertinib Sensitive: C3 – Early Trials
OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	carboplatin + pemetrexed Sensitive: C3 – Early Trials	carboplatin + pemetrexed Sensitive: C3 – Early Trials
MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	carboplatin + pemetrexed Sensitive: C3 – Early Trials	carboplatin + pemetrexed Sensitive: C3 – Early Trials
MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	MUTYH Q324H MUTYH Q324H	Lung Adenocarcinoma LUAD	cisplatin Sensitive: C3 – Early Trials	cisplatin Sensitive: C3 – Early Trials
OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	OGG1 S326C OGG1 S326C	Lung Adenocarcinoma LUAD	cisplatin Sensitive: C3 – Early Trials	cisplatin Sensitive: C3 – Early Trials
EGFR mutation + MDM4 32C>A EGFR mutation + MDM4 32C>A	Lung Adenocarcinoma LUAD	EGFR mutation + MDM4 32C>A EGFR mutation + MDM4 32C>A	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
KEAP1 mutation + MSI-L/dMMR KEAP1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	KEAP1 mutation + MSI-L/dMMR KEAP1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
IFI27 underexpression IFI27 underexpression	Lung Adenocarcinoma LUAD	IFI27 underexpression IFI27 underexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR overexpression EGFR overexpression	Lung Adenocarcinoma LUAD	EGFR overexpression EGFR overexpression	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials	pemetrexed Sensitive: C3 – Early Trials
ALK positive ALK positive	Lung Adenocarcinoma LUAD	ALK positive ALK positive	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials	pemetrexed Sensitive: C3 – Early Trials
ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	ROS1 rearrangement ROS1 rearrangement	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR exon 21 mutation EGFR exon 21 mutation	Lung Adenocarcinoma LUAD	EGFR exon 21 mutation EGFR exon 21 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	EGFR exon 19 mutation EGFR exon 19 mutation	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR mutation + PIK3CA mutation EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma LUAD	EGFR mutation + PIK3CA mutation EGFR mutation + PIK3CA mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR mutation + TP53 mutation EGFR mutation + TP53 mutation	Lung Adenocarcinoma LUAD	EGFR mutation + TP53 mutation EGFR mutation + TP53 mutation	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Resistant: C3 – Early Trials	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	EGFR T790M EGFR T790M	Lung Adenocarcinoma LUAD	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	TP53 mutation + KRAS mutation TP53 mutation + KRAS mutation	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	STK11 deletion + KRAS mutation STK11 deletion + KRAS mutation	Lung Adenocarcinoma LUAD	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
CD74-NRG1 fusion CD74-NRG1 fusion	Lung Adenocarcinoma LUAD	CD74-NRG1 fusion CD74-NRG1 fusion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
YBX1 overexpression YBX1 overexpression	Lung Adenocarcinoma LUAD	YBX1 overexpression YBX1 overexpression	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
SMARCA4 mutation SMARCA4 mutation	Lung Adenocarcinoma LUAD	SMARCA4 mutation SMARCA4 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation PBRM1 mutation	Lung Adenocarcinoma LUAD	PBRM1 mutation PBRM1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation + MSI-L/dMMR PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	PBRM1 mutation + MSI-L/dMMR PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation + TMB-L + MSI-L/dMMR BRAF mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	BRAF mutation + TMB-L + MSI-L/dMMR BRAF mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
PBRM1 mutation + TMB-L + MSI-L/dMMR PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	PBRM1 mutation + TMB-L + MSI-L/dMMR PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
BRAF mutation + MSI-L/dMMR BRAF mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	BRAF mutation + MSI-L/dMMR BRAF mutation + MSI-L/dMMR	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	erlotinib Resistant: C3 – Early Trials	erlotinib Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	EGFR mutation + PD-L1 overexpression EGFR mutation + PD-L1 overexpression	Lung Adenocarcinoma LUAD	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
SDC4-NRG1 fusion SDC4-NRG1 fusion	Lung Adenocarcinoma LUAD	SDC4-NRG1 fusion SDC4-NRG1 fusion	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	HER-2 mutation HER-2 mutation	Lung Adenocarcinoma LUAD	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	KRAS mutation KRAS mutation	Lung Adenocarcinoma LUAD	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
POLD1 C284Y POLD1 C284Y	Lung Adenocarcinoma LUAD	POLD1 C284Y POLD1 C284Y	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
MET D1010N MET D1010N	Lung Adenocarcinoma LUAD	MET D1010N MET D1010N	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C3 – Early Trials	crizotinib Sensitive: C3 – Early Trials
SCN8A Q225X SCN8A Q225X	Lung Adenocarcinoma LUAD	SCN8A Q225X SCN8A Q225X	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials

Lung Adenocarcinoma

Associations(389)

Associations
(389)